INBX Inhibrx Inc.

16.97
+0.26  (+2%)
Previous Close 16.71
Open 16.49
52 Week Low 14.27
52 Week High 50.97
Market Cap $641,641,656
Shares 37,810,351
Float 22,429,310
Enterprise Value $540,600,965
Volume 32,722
Av. Daily Volume 104,073
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
INBRX-109
Chondrosarcoma and mesothelioma
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
INBRX-105 and Keytruda
Solid Tumors
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
INBRX-106
Solid Tumors
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
INBRX-101
Alpha-1 Antitrypsin Deficiency
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Latest News

  1. SAN DIEGO, May 17, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conferences:

    • Jefferies Healthcare Conference; Wednesday, June 2nd at 12:30 p.m. Pacific Time
    • JMP Securities Life Sciences Conference; Thursday, June 17th at 8:00 a.m. Pacific Time

    The investor conference presentations will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The webcasts will be available for 60 days following the event.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

    Investor and Media Contact:

    Amy Conrad

    Juniper Point



    858-366-3243

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-investor-conferences-301291482.html

    SOURCE Inhibrx, Inc.

    View Full Article Hide Full Article
  2. SAN DIEGO, May 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, today reported financial results for the first quarter of 2021.

    "This past quarter, we continued to make significant progress advancing our clinical programs and are on track to deliver data from all four programs later this year," said the Company's Chief Executive Officer, Mark Lappe. "April 2021 marked 11 years of Inhibrx dedicated to developing novel, best-in-class therapeutics for the treatment of cancer and rare diseases, and we remain strongly encouraged that we will deliver on our mission."

    Financial Results

    • Cash and Cash Equivalents. As of March 31, 2021, Inhibrx had cash and cash equivalents of $108.0

    SAN DIEGO, May 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, today reported financial results for the first quarter of 2021.

    "This past quarter, we continued to make significant progress advancing our clinical programs and are on track to deliver data from all four programs later this year," said the Company's Chief Executive Officer, Mark Lappe. "April 2021 marked 11 years of Inhibrx dedicated to developing novel, best-in-class therapeutics for the treatment of cancer and rare diseases, and we remain strongly encouraged that we will deliver on our mission."

    Financial Results

    • Cash and Cash Equivalents. As of March 31, 2021, Inhibrx had cash and cash equivalents of $108.0 million, compared to $128.7 million as of December 31, 2020.
    • R&D Expense. Research and development expenses were $16.4 million during the first quarter of 2021, compared to $17.0 million during the first quarter of 2020. This overall decrease was primarily due to the timing of work performed by Inhibrx's contract development and manufacturing organization partners for the formulation and manufacturing of certain of its therapeutic candidates, offset in part by an increase in headcount and personnel-related costs due to the continued expansion of its organization.
    • G&A Expense. General and administrative expenses were $3.0 million during the first quarter of 2021, compared to $1.5 million during the first quarter of 2020. This increase was primarily due to an increase in personnel-related costs and other expenses associated with operating as a public company.
    • Net Loss. Net loss was $19.3 million during the first quarter of 2021, or $0.51 per share, compared to $20.1 million during the first quarter of 2020, or $1.11 per share.

    About the Inhibrx sdAb Platform

    Inhibrx utilizes diverse methods of protein engineering in the construction of therapeutic candidates that can address the specific requirements of complex target and disease biology. A key tool for this effort is the Inhibrx proprietary sdAb platform, which enables the development of therapeutic candidates with attributes superior to other monoclonal antibody and fusion protein approaches. This platform allows the combination of multiple binding units in a single molecule, enabling the creation of therapeutic candidates with defined valency or multiple specificities that can achieve enhanced cell signaling or conditional activation. An additional benefit of this platform is that these optimized, multi-functional entities can be manufactured using the established processes that are commonly used to produce therapeutic proteins.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

    Forward Looking Statements

    Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: future clinical development Inhibrx's therapeutic candidates, including statements regarding expected therapeutic benefit, the timing of future clinical development and evaluations and judgments regarding Inhibrx's therapeutic candidates. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its expectations regarding the impact of the COVID-19 pandemic on its business; and other risks described in Inhibrx's filings with the U.S. Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in Inhibrx's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Investor and Media Contact:

    Amy Conrad

    Juniper Point



    858-366-3243

     

    Inhibrx, Inc.

    Condensed Consolidated Statements of Operations

    (In thousands, except per share data)







    THREE MONTHS ENDED MARCH 31,



    2021



    2020



    (unaudited)

    Revenue:







    License fee revenue

    $

    863





    $

    872



    Grant revenue

    26







    Total revenue

    889





    872



    Operating expenses:







    Research and development

    16,438





    17,016



    General and administrative

    3,009





    1,467



    Total operating expenses

    19,447





    18,483



    Loss from operations

    (18,558)





    (17,611)



    Total other income (expense)

    (729)





    (2,482)



    Provision for income taxes

    2







    Net loss

    $

    (19,289)





    $

    (20,093)



    Net loss per share, basic and diluted

    $

    (0.51)





    $

    (1.11)



    Weighted-average shares of common stock outstanding, basic and diluted

    37,736





    18,154



     



     

    Inhibrx, Inc.

    Condensed Consolidated Balance Sheets

    (In thousands) 











    MARCH 31,



    DECEMBER 31,



    2021



    2020



    (unaudited)













    Cash and cash equivalents

    $

    107,990





    $

    128,664



    Other current assets

    5,412





    3,508



    Non-current assets

    11,102





    11,568



    Total assets

    $

    124,504





    $

    143,740











    Debt, current and non-current

    $

    29,445





    $

    29,244



    Other current liabilities

    27,850





    31,399



    Other non-current liabilities

    6,616





    7,624



    Total liabilities

    63,911





    68,267



    Stockholders' equity

    60,593





    75,473



    Total liabilities and stockholders' equity

    $

    124,504





    $

    143,740



     

    Cision View original content:http://www.prnewswire.com/news-releases/inhibrx-reports-first-quarter-2021-financial-results-301290427.html

    SOURCE Inhibrx, Inc.

    View Full Article Hide Full Article
  3. SAN DIEGO, March 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and announced results from the single agent dose escalation of the Phase 1 study of INBRX-105.

    Mark Lappe, Inhibrx's CEO commented, "2020 was a transformative year for Inhibrx. We made substantive advances in our four clinical programs across oncology and orphan disease, continued to progress our pre-clinical pipeline, and successfully completed an initial public offering."

    Phase 1 Dose Escalation Results for INBRX-105

    INBRX-105 is a precisely engineered multi-specific therapeutic candidate based on our single domain antibody (sdAb…

    SAN DIEGO, March 12, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a biotechnology company with four clinical programs in development, today reported financial results for the fourth quarter and fiscal year 2020, and announced results from the single agent dose escalation of the Phase 1 study of INBRX-105.

    Mark Lappe, Inhibrx's CEO commented, "2020 was a transformative year for Inhibrx. We made substantive advances in our four clinical programs across oncology and orphan disease, continued to progress our pre-clinical pipeline, and successfully completed an initial public offering."

    Phase 1 Dose Escalation Results for INBRX-105

    INBRX-105 is a precisely engineered multi-specific therapeutic candidate based on our single domain antibody (sdAb) platform that is designed to agonize 4-1BB selectively in the presence of programmed death ligand 1 (PD-L1), a protein that is typically found in the tumor microenvironment and lymphoid tissues.

    The study is a first-in-human, multicenter, open-label, non-randomized, Phase 1 trial in patients with locally advanced or metastatic solid tumors. The trial is designed to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose of INBRX-105 administered as a single agent or in combination with Keytruda® (pembrolizumab), a programmed death receptor-1 (PD-1) checkpoint inhibitor. Single agent dose escalation was completed with a total of 32 patients enrolled. We observed dose-limiting toxicities, which were consistent with immune related adverse events (for example, hepatitis, arthritis and myalgia/hyperthyroidism) at several dose levels and determined the 1 mg/kg dose level as the MTD of INBRX-105. Patients were not pre-screened for PD-L1 expression. Eight out of 18 evaluable patients (44%) receiving INBRX-105 at dose levels equal to or greater than 0.1 mg/kg achieved stable disease, with the greatest reduction in tumor volume observed to be 20% by RECISTv1.1. The longest duration on treatment with INBRX-105 was 41 weeks, or approximately nine and a half months. Notably, seven patients with stable disease tested positive for PD-L1 expression, with a minimum of 1% positivity as determined by immunohistochemistry (Range 1 to 95%), and the results of one patient are pending. Four of these eight patients were refractory to or progressed on prior PD-1 checkpoint inhibitors.

    We expect to achieve the maximal therapeutic benefit of INBRX-105 in combination with PD-1 checkpoint blockade. In our preclinical studies we observed that acute exposure to PD-L1 dependent 4-1BB agonism was sufficient to derive maximal anti-tumor activity when co-dosed with another PD-1 blocking agent at a target saturating dose. As such, a dose escalation cohort of INBRX-105 in combination with Keytruda® is targeted to initiate enrollment during the second quarter of 2021 and we expect to announce initial data during the fourth quarter of 2021.

    Financial Results

    • Cash and Cash Equivalents. Cash and cash equivalents totaled $128.7 million as of December 31, 2020, compared to $11.5 million as of December 31, 2019. Cash and cash equivalents totaled $111.3 million as of February 28, 2021.
    • R&D Expense. Research and development expense was $17.7 million during the fourth quarter of 2020, as compared to $12.3 million during the fourth quarter of 2019. Research and development expense was $73.5 million during the fiscal year 2020, as compared to $47.9 million during the fiscal year 2019.  These increases were primarily due to an increase in contract manufacturing expense for scale-up activities performed by Inhibrx's contract development and manufacturing organization partners for its INBRX-109 and INBRX-101 programs. Additionally, clinical research organization costs increased due to the progression of its Phase 1 trials.
    • G&A Expense. General and administrative, or G&A, expense was $2.2 million during the fourth quarter of 2020, as compared to $1.7 million during the fourth quarter of 2019. G&A expense was $6.8 million during the fiscal year 2020, as compared to $6.3 million during the fiscal year 2019. These increases were primarily due to increases in Inhibrx's personnel-related expenses due to increased headcount and increased rent expense under its amended building lease.
    • Net Loss. Net loss was $17.6 million during the fourth quarter of 2020, or a net loss per share of $0.47, as compared to a net loss of $16.3 million during the fourth quarter of 2019, or a net loss per share of $0.90. Net loss was $76.1 million during the fiscal year 2020, or a net loss per share of $3.01, as compared to a net loss of $51.4 million during the fiscal year 2019, or a net loss per share of $2.83.

    Inhibrx Corporate Presentation

    Inhibrx has also updated its corporate presentation which is available on the "Investors" section of its website at www.inhibrx.com.

    About the Inhibrx sdAb Platform

    Inhibrx utilizes diverse methods of protein engineering in the construction of therapeutic candidates that can address the specific requirements of complex target and disease biology. A key tool for this effort is the Inhibrx proprietary sdAb platform, which enables the development of therapeutic candidates with attributes superior to other monoclonal antibody and fusion protein approaches. This platform allows the combination of multiple binding units in a single molecule, enabling the creation of therapeutic candidates with defined valency or multiple specificities that can achieve enhanced cell signaling or conditional activation. An additional benefit of this platform is that these optimized, multi-functional entities can be manufactured using the established processes that are commonly used to produce therapeutic proteins.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

    Forward Looking Statements

    Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: future clinical development Inhibrx's therapeutic candidates, including statements regarding expected therapeutic benefit, the timing of future clinical development and evaluations and judgments regarding Inhibrx's therapeutic candidates. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its expectations regarding the impact of the COVID-19 pandemic on its business; and other risks described in Inhibrx's filings with the U.S. Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in Inhibrx's Quarterly Report on Form 10-Q for the period ended September 30, 2020, as filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Investor and Media Contact:

    Amy Conrad

    Juniper Point



    858-366-3243



    Inhibrx, Inc

    Condensed Consolidated Statements of Operations

    (In thousands, except per share data)





    THREE MONTHS ENDED DECEMBER 31,



    YEAR ENDED

    DECEMBER 31,



    2020



    2019



    2020



    2019

    Revenue:















    License fee revenue

    $

    2,776





    $

    267





    $

    12,808





    $

    9,093



    Grant revenue





    (4)





    80





    4,118



    Total revenue

    2,776





    263





    12,888





    13,211



    Operating expenses:















    Research and development

    17,668





    12,283





    73,495





    47,907



    General and administrative

    2,215





    1,673





    6,836





    6,257



    Abandoned offering costs





    2,761









    2,761



    Total operating expenses

    19,883





    16,717





    80,331





    56,925



    Loss from operations

    (17,107)





    (16,454)





    (67,443)





    (43,714)



    Total other income (expense)

    (539)





    149





    (8,191)





    (6,788)



    Provision for income taxes

    3









    3





    898



    Loss on equity method investment









    487







    Net loss

    (17,649)





    (16,305)





    $

    (76,124)





    $

    (51,400)



    Net loss per share, basic and diluted

    $

    (0.47)





    $

    (0.90)





    $

    (3.01)





    $

    (2.83)



    Weighted-average shares of common stock outstanding, basic and diluted

    37,712





    18,154





    25,261





    18,154









    Inhibrx, Inc

    Condensed Consolidated Balance Sheets

    (In thousands)





    AS OF DECEMBER 31,



    2020



    2019









    Cash and cash equivalents

    $

    128,664





    $

    11,540



    Other current assets

    3,508





    4,021



    Non-current assets

    11,568





    10,928



    Total assets

    $

    143,740





    26,489











    Debt, current and non-current

    $

    29,244





    $

    3,563



    Other current liabilities

    31,399





    17,007



    Convertible notes





    30,367



    Other non-current liabilities

    7,624





    9,614



    Total liabilities

    68,267





    60,551



    Convertible preferred stock





    59,507



    Stockholders' equity (deficit)

    75,473





    (93,569)



    Total liabilities, convertible preferred stock and stockholders' equity (deficit)

    $

    143,740





    $

    26,489



     

    Cision View original content:http://www.prnewswire.com/news-releases/inhibrx-reports-fourth-quarter-and-fiscal-year-2020-financial-results-and-announces-phase-1-single-agent-dose-escalation-results-for-inbrx-105-a-novel-targeted-4-1bb-agonist-301245665.html

    SOURCE Inhibrx, Inc.

    View Full Article Hide Full Article
  4. SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference:

    • Guggenheim Healthcare Talks: 2021 Oncology Days; Friday, February 12th, at 2 p.m. Pacific Time

    The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The webcast will be available for 60 days following the event.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing…

    SAN DIEGO, Feb. 1, 2021 /PRNewswire/ -- Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today that the Company will be presenting at the following upcoming virtual investor conference:

    • Guggenheim Healthcare Talks: 2021 Oncology Days; Friday, February 12th, at 2 p.m. Pacific Time

    The investor conference presentation will be webcast live and may be accessed through a link on the investors section of Inhibrx's website at https://inhibrx.investorroom.com/events-and-presentations. The webcast will be available for 60 days following the event.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. Inhibrx has collaborations with bluebird bio, Bristol-Myers Squibb and Chiesi. For more information, please visit www.inhibrx.com.

    Investor and Media Contact:

    Amy Conrad

    Juniper Point



    858-366-3243

    Cision View original content:http://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-investor-conference-301219478.html

    SOURCE Inhibrx, Inc.

    View Full Article Hide Full Article
  5. SAN DIEGO, Jan. 13, 2021 /PRNewswire/ -- Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company with a broad pipeline of biotherapeutics in development, announced today the U.S. Food and Drug Administration (FDA) granted Fast Track designation to INBRX-109 for the treatment of patients with unresectable or metastatic conventional chondrosarcoma. INBRX-109 is a precisely engineered tetravalent single domain antibody (sdAb)-based therapeutic candidate that agonizes death receptor 5 (DR5) to induce tumor selective programmed cell death.

    Fast Track designation is granted by the FDA upon the request of the sponsor to facilitate the development and expedite the review of drugs intended to treat serious or life-threatening diseases. Depending upon the stage of the product's development, the sponsor must also provide FDA with nonclinical or clinical data to demonstrate the drug's potential to address unmet medical needs for such a disease or condition. Investigational drug products with Fast Track designation may benefit from early and frequent communication with the FDA, and are eligible for rolling submission and FDA review of its future marketing application. The designation was granted to INBRX-109 based on preliminary data from the chondrosarcoma expansion cohort of the Phase 1 clinical trial of INBRX-109.

    "There are currently no approved agents for the treatment of unresectable or metastatic conventional chondrosarcoma, and we are excited about the potential of this treatment to meaningfully improve the outcome for patients," said Mark Lappe, CEO of Inhibrx. "We look forward to working closely with the FDA throughout the clinical development of INBRX-109."

    A potential registration-enabling Phase 2 study of INBRX-109 has been discussed with the FDA and will be designed as a randomized, blinded, placebo-controlled study in unresectable or metastatic conventional chondrosarcoma with progression-free survival as the primary endpoint. Inhibrx expects to start dosing patients in this potentially registration-enabling study in the second or third quarter of this year.

    About the Inhibrx sdAb Platform

    Inhibrx utilizes diverse methods of protein engineering in the construction of therapeutic candidates that can address the specific requirements of complex target and disease biology. A key tool for this effort is the Inhibrx proprietary sdAb platform, which enables the development of therapeutic candidates with attributes superior to other monoclonal antibody and fusion protein approaches. This platform allows the combination of multiple binding units in a single molecule, enabling the creation of therapeutic candidates with defined valency or multiple specificities, potentially capable of enhanced cell signaling or conditional activation. An additional benefit of this platform, these optimized, multi-functional entities can be manufactured using the established processes that are commonly used to produce therapeutic proteins.

    Initially, Inhibrx is pursuing targets with early clinical validation, such as DR5, where other therapeutics have demonstrated liabilities. In addition, Inhibrx is developing a portfolio of sdAb based therapeutic candidates in a variety of indications for both known and novel targets.

    About Inhibrx, Inc.

    Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to therapeutically address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is currently focused on oncology and orphan diseases. Inhibrx has collaborations with bluebird bio, Celgene and Chiesi. For more information, please visit www.inhibrx.com.

    Forward Looking Statements

    Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: Inhibrx's and its investigators judgments and beliefs regarding the observed or potential safety and efficacy of its therapeutic candidates in clinical trials and beliefs regarding the future clinical development of INBRX-109, including its ability to conduct any registration-enabling study. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its expectations regarding the impact of the COVID-19 pandemic on its business; and other risks described in Inhibrx's filings with the U.S. Securities and Exchange Commission (the "SEC"), including under the heading "Risk Factors" in Inhibrx's Form 10-Q for the quarter ended September 30, 2020 filed with the SEC on November 13, 2020 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Inhibrx undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

    Investor and Media Contact:

    Amy Conrad

    Juniper Point



    858-366-3243

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inhibrx-granted-fast-track-designation-for-inbrx-109-for-the-treatment-of-unresectable-or-metastatic-conventional-chondrosarcoma-patients-301207158.html

    SOURCE Inhibrx Inc. / Juniper Point

    View Full Article Hide Full Article
View All Inhibrx Inc. News